Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism

Oral DHEA administration to patients with hypoadrenalism, in addition to glucocorticoid and mineralcorticoid replacement, may improve both well-being and hormonal/metabolic parameters. Twenty patients (13 men, 7 women, 26-76 yr, 11 with Addison's disease, 9 with central hypoadrenalism) were recruited in a placebo-controlled, randomized study. Hormone levels, carbohydrate and lipid parameters, bone metabolism, body composition and psychological parameters were evaluated at baseline and after treatment with DHEA 50 mg/day or placebo for 4 months. After 4 months of DHEA administration, serum DHEAS levels raised both in men (from 0.71\ub10.18 to 8.28\ub11.66 \u3bcmol/l, p<0.005) and in women (from 0.25\ub10.07 to 5.65\ub11.93 \u3bcmol/l, p<0.05). Only in hypoadrenal women an increase in testosterone (T; from 0.4\ub10.1 to 1.45\ub10.26 nmol/l, p<0.05) and androstenedione (A; from 0.86\ub10.34 to 2.05\ub10.29 nmol/l, p<0.05) levels was observed. In men no significant modifications in T and 17-hydroxyprogesterone (1 7-OHP) levels were found, whereas serum SHBG significantly decreased. As far as the metabolic parameters are concerned, only in patients with Addison's disease a significant decrease in total cholesterol and in low-density lipoproteins after 4 months of DHEA administration was found. No changes in glucose metabolism and insulin sensitivity were observed. In basal conditions, mean serum osteocalcin (OC) was normal and significantly decreased after DHEA treatment. A significant reduction in body fat mass percentage (BF% after DHEA administration was observed. As far as well-being is concerned, DHEA replacement did not cause any relevant variation of subjective health scales and sexuality in both sexes. Our study confirms that DHEA may be beneficial for female patients with hypoadrenalism, mainly in restoring androgen levels. Concerning the health status, more sensitive and specific instruments to measure the effects of DHEA treatment could be necessary

Microstructure and anti- wear and corrosion performances of novel UHMWPE/graphene-nanosheet composite coatings deposited by flame spraying

Ultra-high molecular weight polyethylene (UHMWPE)/graphene-nanosheet (GN, multiple layers of graphene sheets with the thickness of ~5–10？nm) coatings have been deposited by flame spraying. The structure of UHMWPE remained almost intact after the spray processing and addition of GNs resulted in a slightly decreased crystallinity and improved thermal stability of UHMWPE. In addition, the coating containing 1.0？wt.% GNs exhibited a reduction of ~20% in wear rate and 25% in friction coefficient (0.18 versus 0.24). Significantly enhanced anti-corrosion performances of the UHMWPE–GN coatings were suggested by increased corrosion potential, corrosion current density, and impedance modulus value of the UHMWPE–GN coatings. The very well retained GNs are located mainly at the interfaces between UHMWPE splats and act as bridges connecting the splats, which mainly accounts for the enhanced properties of the composite coatings. The novel UHMWPE–graphene composite coatings show great potential for protecting engineering components for applications against corrosion

A Primary adrenal non-hodgkin's lymphoma presenting as an incidental adrenal mass

The primary adrenal localization of a non-Hodgkin's lymphoma (NHL) is a rare event. We report the case of a 70-yr-old woman, who was admitted at our Institute for a hormonal evaluation after the incidental discovery of a right adrenal mass during ultrasonography (US) performed for cardiovascular disease. At the physical examination, no sign of adrenal hyperfunction was present. She showed only an androgenetic alopecia and her blood pressure was 180/70 mm Hg, with an arrhythmic heart rate of 100 beats/min. No alterations in hormonal and biochemical data were observed. US studies showed a right adrenal mass (major diameter 16 mm), and an abdominal computed tomography (CT) scan confirmed this solid lesion (major diameter 15 mm) with a high density. [75Se] methylnorcholesterol adrenal scintigraphy exhibited a normal symmetrical radiotracer uptake. After 8 months of follow-up, an abdominal CT scan demonstrated a significant increase of the right adrenal mass (major diameter: 40 mm), with a solid tissue density and enhancement after i.v. contrast. [ 75Se] methylnorcholesterol adrenal scintigraphy showed an absent uptake on the right side versus the contralateral side. The hematological, hormonal and radiological evaluation did not reveal any sign of malignancy. Owing to the mass enlargement and the modification of scintigraphic pattern, the patient underwent unilateral adrenalectomy. Histological examination revealed a primary diffuse large B-cell NHL (REAL classification) of the adrenal gland. After surgery, she underwent a combined polychemotherapy (cyclophospamide, adriamycin, vincristine and prednisone) and subsequently one cycle of radiotherapy. At present, the patient is in good conditions and there are no signs or symptoms of recurrent disease

Tic21 is an essential translocon component for protein translocation across the chloroplast inner envelope membrane

have been edited and the authors have corrected proofs, but before the final, complete issue is published online. Early posting of articles reduces normal time to publication by several weeks